"We are judiciously looking at our products in the biopharmaceutical business to ensure we sustain the improved margin. Biopharmaceutical grew moderately only by 4% because during Q2 the revenues spiked largely contributed by global tenders that we won. This particular quarter didn't see much contribution from global tenders, given the fact that these tenders happens only at certain times of the year. In the next quarter, this aberration that we see will be corrected as we move ahead," opined Dr Kiran.

Dr Kiran revealed that the company's R&D spend has been relatively low.

"We have incurred roughly 20-21 crore R&D expense which is sharply down from our previous two quarters where we spent 40 crore and upwards. This aberration is largely of the fact that our clinical trials environment in the country which has put many of our clinical trials on hold," she added.

At the same time, Dr Kiran expressed much satisfaction on clinical trials program that are making good progress in other countries.

"The outlook for the next quarter looks very good and I'm confident that we'll end the year on high," she added.